吉林大学学报(医学版) ›› 2022, Vol. 48 ›› Issue (6): 1644-1649.doi: 10.13481/j.1671-587X.20220634
收稿日期:
2022-02-10
出版日期:
2022-11-28
发布日期:
2022-12-07
通讯作者:
陈艳
E-mail:chenyanfeihong0906@163.com
作者简介:
张树辉(1995-),男,山东省菏泽市人,在读硕士研究生, 主要从事神经调控治疗胃肠道疾病方面的研究。
基金资助:
Received:
2022-02-10
Online:
2022-11-28
Published:
2022-12-07
摘要:
肠道微生物群系主要包括细菌、真菌、病毒和蠕虫等,在肠道保护屏障和肠道免疫反应中发挥重要作用。炎症性肠病所引起的肠道功能障碍常常伴随着肠道微生物群系的失调,通常表现为多样性下降、致炎微生物增加及抗炎微生物的减少。目前炎症性肠病中肠道微生物群系的研究以细菌方面为主,但也有研究证明真菌、病毒和蠕虫等在炎症性肠病的发生发展中发挥了重要作用。目前已有肠道微生物群系来改善肠道炎症的治疗方法,如粪菌移植和饮食习惯治疗等,现有的药物治疗也被认为可以通过影响肠道微生物群系来发挥作用,肠道微生物群系已成为炎症性肠病的治疗重点。现对细菌、病毒、真菌和蠕虫等在炎症性肠病发生发展过程中的影响进行综述,并对通过改变肠道微生物群系进行炎症性肠病的治疗方法进行回顾总结,为炎症性肠病的治疗提供新的思路。
中图分类号:
张树辉,张灿,秘晨晓,陈艳. 肠道微生物群系对炎症性肠病发生发展影响的研究进展Research progress in effect of intestinal microflora on occurrence and development of inflammatory bowel disease[J]. 吉林大学学报(医学版), 2022, 48(6): 1644-1649.
1 | ZHANG N N, ZHANG H, JIANG L Q, et al. A novel method of sacral nerve stimulation for colonic inflammation[J].Neurogastroenterol Motil,2020,32(6): e13825. |
2 | ANSALDO E, FARLEY T K, BELKAID Y. Control of immunity by the microbiota[J]. Annu Rev Immunol, 2021, 39: 449-479. |
3 | HERNÁNDEZ M, CANFORA E E, JOCKEN J W E, et al. The short-chain fatty acid acetate in body weight control and insulin sensitivity[J].Nutrients,2019,11(8): 1943. |
4 | DUDIK B, SEPOVA H K, BILKOVA A. Inflammatory bowel disease: factors involved in pathogenesis[J]. Ceska Slov Farm,2018,67(3):95-100. |
5 | KUSHKEVYCH I, DORDEVIĆ D, KOLLAR P,et al. Hydrogen sulfide as a toxic product in the small-large intestine axis and its role in IBD development[J]. J Clin Med, 2019, 8(7): 1054. |
6 | GEVERS D, KUGATHASAN S, KNIGHTS D,et al. A microbiome foundation for the study of Crohn’s disease[J]. Cell Host Microbe, 2017, 21(3): 301-304. |
7 | BELKAID Y, HAND T W. Role of the microbiota in immunity and inflammation[J]. Cell, 2014, 157(1): 121-141. |
8 | GONZÁLEZ OLMO B M, BUTLER M J, BARRIENTOS R M. Evolution of the human diet and its impact on gut microbiota, immune responses, and brain health[J]. Nutrients, 2021, 13(1): 196. |
9 | MORGAN X C, TICKLE T L, SOKOL H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment[J]. Genome Biol, 2012, 13(9): R79. |
10 | MOTTAWEA W, CHIANG C K, MÜHLBAUER M, et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease[J]. Nat Commun, 2016, 7: 13419. |
11 | GRACIE D J, HAMLIN P J, FORD A C. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment[J]. Lancet Gastroenterol Hepatol, 2019, 4(8): 632-642. |
12 | SINGH V, KUMAR M, BSAN YEOH, et al. Inhibition of interleukin-10 signaling induces microbiota-dependent chronic colitis in apolipoprotein E deficient mice[J]. Inflamm Bowel Dis, 2016, 22(4): 841-852. |
13 | FRANZOSA E A, SIROTA-MADI A, AVILA-PACHECO J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease[J]. Nat Microbiol, 2019, 4(2): 293-305. |
14 | KIM M J, KIM E, KANG B, et al.Anti-Saccharomyces cerevisiae antibody in pediatric Crohn’s disease patients without mucosal healing is a useful marker of mucosal damage[J]. Gut Liver, 2021, 15(5): 763-770. |
15 | GUGGINO G, MAURO D, RIZZO A, et al. Inflammasome activation in ankylosing spondylitis is associated with gut dysbiosis[J]. Arthritis Rheumatol, 2021, 73(7): 1189-1199. |
16 | MUKHOPADHYA I, HANSEN R, MEHARG C,et al.The fungal microbiota of de-novo paediatric inflammatory bowel disease[J]. Microbes Infect, 2015, 17(4): 304-310. |
17 | LIGUORI G, LAMAS B, RICHARD M L, et al. Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients[J]. J Crohns Colitis, 2016, 10(3): 296-305. |
18 | SASSON A N, INGRAM R J M, ZHANG Z X, et al. The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease[J]. Lancet Gastroenterol Hepatol, 2021, 6(9): 754-769. |
19 | JAIN U, MVER HEUL A, XIONG S S, et al. Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice[J]. Science, 2021, 371(6534): 1154-1159. |
20 | DORON I, MESKO M, LI X V, et al. Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohn’s disease[J]. Nat Microbiol, 2021, 6(12): 1493-1504. |
21 | TRUNK K, PELTIER J, LIU Y C, et al. The type Ⅵsecretion system deploys antifungal effectors against microbial competitors[J]. Nat Microbiol, 2018, 3(8): 920-931. |
22 | FILYK H A, OSBORNE L C. The multibiome: the intestinal ecosystem’s influence on immune homeostasis,health, and disease[J]. EBioMedicine, 2016, 13: 46-54. |
23 | LAMAS B, RICHARD M L, LEDUCQ V, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands[J]. Nat Med, 2016, 22(6): 598-605. |
24 | COSNES J, GOWER-ROUSSEAU C, SEKSIK P,et al.Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology, 2011,140(6):1785-1794. |
25 | XU J Y, YU P C, WU L J, et al. Effect of Trichinella spiralis intervention on TNBS-induced experimental colitis in mice[J].Immunobiology, 2019,224(1): 147-153. |
26 | PANELLI S, EPIS S, COCOCCIONI L, et al. Inflammatory bowel diseases, the hygiene hypothesis and the other side of the microbiota: parasites and fungi[J]. Pharmacol Res, 2020, 159: 104962. |
27 | VARELA E, MANICHANH C, GALLART M, et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis[J]. Aliment Pharmacol Ther, 2013, 38(2): 151-161. |
28 | SOKOL H, PIGNEUR B, WATTERLOT L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients[J]. Proc Natl Acad Sci U S A, 2008, 105(43): 16731-16736. |
29 | YUAN H D, MA Q Q, CUI H Y, et al. How can synergism of traditional medicines benefit from network pharmacology? [J]. Molecules, 2017, 22(7): 1135. |
30 | REYES A, HAYNES M, HANSON N, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers[J]. Nature, 2010, 466(7304): 334-338. |
31 | KHARDORI N, STEVAUX C, RIPLEY K. Antibiotics: from the beginning to the future: part 2[J]. Indian J Pediatr, 2020, 87(1): 43-47. |
32 | NORMAN J M, HANDLEY S A, BALDRIDGE M T, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease[J].Cell, 2015,160(3):447-460. |
33 | CLOONEY A G, SUTTON T D S, SHKOPOROV A N, et al. Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease[J]. Cell Host Microbe, 2019, 26(6): 764-778.e5. |
34 | SHKOPOROV A N, CLOONEY A G, SUTTON T D S, et al. The human gut virome is highly diverse, stable, and individual specific[J]. Cell Host Microbe, 2019, 26(4): 527-541.e5. |
35 | DUAN Y, YOUNG R, SCHNABL B. Bacteriophages and their potential for treatment of gastrointestinal diseases[J].Nat Rev Gastroenterol Hepatol,2022,19(2): 135-144. |
36 | ANDREWS C N, GRIFFITHS T A, KAUFMAN J, et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2011, 34(3): 374-383. |
37 | NISHIDA A, INOUE R, INATOMI O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease[J]. Clin J Gastroenterol, 2018, 11(1): 1-10. |
38 | PITCHER M C, BEATTY E R, CUMMINGS J H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis[J]. Gut, 2000, 46(1): 64-72. |
39 | BUSQUETS D, MAS-DE-XAXARS T, LÓPEZ-SILES M,et al. Anti-tumour necrosis factor treatment with adalimumab induces changes in the microbiota of Crohn’s disease[J].J Crohns Colitis,2015,9(10): 899-906. |
40 | FLORIN T H J, WRIGHT J D, JAMBHRUNKAR S D,et al. A well-tolerated and rapidly acting thiopurine for IBD? [J]. Drug Discov Today, 2019, 24(1): 37-41. |
41 | HUANG E Y, INOUE T, LEONE V A, et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2015, 21(5): 963-972. |
42 | SIPPOLA S, HAIJANEN J, GRÖNROOS J, et al. Effect of oral moxifloxacin vs intravenous ertapenem plus oral levofloxacin for treatment of uncomplicated acute appendicitis: the APPAC II randomized clinical trial[J]. JAMA, 2021, 325(4): 353-362. |
43 | ABENAVOLI L, SCARPELLINI E, COLICA C,et al. Gut microbiota and obesity: a role for probiotics[J]. Nutrients, 2019, 11(11): 2690. |
44 | BUTTERWORTH A D, THOMAS A G, AKOBENG A K. Probiotics for induction of remission in Crohn’s disease[J]. Cochrane Database Syst Rev, 2008, 2008(3): CD006634. |
45 | RACHUL C, MARCON A R, COLLINS B, et al. COVID-19 and ‘immune boosting’ on the Internet: a content analysis of Google search results[J]. BMJ Open, 2020, 10(10): e040989. |
46 | QURAISHI M N, WIDLAK M, BHALA N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection[J]. Aliment Pharmacol Ther, 2017, 46(5): 479-493. |
47 | ANDERSON J L, EDNEY R J, WHELAN K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2012, 36(6): 503-516. |
48 | SHA S, LIANG J, CHEN M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children[J]. Aliment Pharmacol Ther, 2014, 39(10): 1003-1032. |
49 | WEINGARDEN A R, VAUGHN B P. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease[J]. Gut Microbes, 2017, 8(3): 238-252. |
50 | 李姗姗, 杨长青. 门静脉高压性肠病——一种不该忽视的门静脉高压并发症[J].临床肝胆病杂志,2022,38(6):1237-1241. |
[1] | 王凯新,董晓梦,苏毅鹏,陈金波. 肠道菌群与抑郁症关系的研究进展[J]. 吉林大学学报(医学版), 2022, 48(4): 1094-1100. |
[2] | 郭泽尚,王磊,常志勇. 电子鼻在肠道疾病诊断中应用的研究进展[J]. 吉林大学学报(医学版), 2020, 46(6): 1332-1337. |
[3] | 陈昂, 王桂兰, 刘翔腾, 张泉山. 早期干预对食物过敏婴儿其他过敏性疾病发生的预防作用[J]. 吉林大学学报(医学版), 2020, 46(04): 851-857. |
[4] | 黄江勇, 李婵秀, 郑志超, 王洪娟, 郭吕华, 吴哲, 罗涛. 益生菌对卵巢摘除致雌激素缺乏小鼠牙周组织中IL-17表达的影响及其意义[J]. 吉林大学学报(医学版), 2020, 46(04): 733-738. |
[5] | 李辉, 魏民华, 张晓岚. IL-10家族在肠纤维化中作用的研究进展[J]. 吉林大学学报(医学版), 2017, 43(04): 849-851. |
[6] | 王丽英, 杨勇, 李占东, 李东复, 刘力宾, 王敏. siRNA干预树突状细胞CD40表达对大鼠炎症性肠病的治疗作用[J]. 吉林大学学报(医学版), 2015, 41(01): 54-59. |
[7] | 郭晓敏,杨桂连,王春凤. 益生菌的免疫调节作用及其在肠道疾病治疗中应用的研究进展[J]. 吉林大学学报(医学版), 2013, 39(4): 859-862. |
[8] | 陈 曦,杨世忠,迟宝荣. 大鼠炎症性肠病模型的复制及中药的干预作用[J]. J4, 2008, 34(2): 262-265. |
[9] | 赵颖,杨世忠, 朴云峰,高普均,王岚,刘明远. 旋毛虫对三硝基苯磺酸诱导肠炎小鼠Th1/Th2类细胞因子基因表达的影响[J]. J4, 2007, 33(1): 67-70. |
[10] | 王 哲,周长玉,韩立坤. 炎症性肠病患者血小板平均体积和D-二聚体检测的临床意义[J]. J4, 2004, 30(6): 947-948. |
|